Boston Trust Walden’s Adient ADNT Stock Holding History

Boston Trust Walden’s Portfolio ADNT Stock Details ADNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,007	Closed	-$219K	–	371
2017 Q1	$219K	Sell	3,007 -1,706	-36%	-$112K	﹤0.01%	344
2016 Q4	$276K	Buy	+4,713	New	+$249K	﹤0.01%	337

Other funds holding ADNT

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

LCM

Lakewood Capital Management New York $1.58B AUM 0.92% 1-Year Est. Return

BHG

Blue Harbour Group Greenwich, Connecticut $353M AUM 8.9% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

BRC

Blue Ridge Capital New York $215M AUM

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Boston Trust Walden's ADNT Position: Q2 2017 in Review

Boston Trust Walden sold out of Adient (ADNT) in Q2 2017, closing a stake of 3,007 shares — an estimated $219K sold.

Boston Trust Walden first reported a position in ADNT in Q4 2016 and held it in 2 quarters. The position peaked at $276K in Q4 2016. 398 funds tracked by Wall St. Rank hold ADNT as of Q2 2017.

Boston Trust Walden reported no remaining Adient position as of Q2 2017 after selling out during the quarter.
Boston Trust Walden sold 3,007 Adient shares in Q2 2017, an estimated $219K.
Boston Trust Walden first reported a position in Adient in Q4 2016 and held it in 2 quarters.
Boston Trust Walden's Adient position peaked at $276K in Q4 2016.
398 funds tracked by Wall St. Rank held Adient as of Q2 2017.

Based on Boston Trust Walden's 13F filing for Q2 2017, filed 19 Jul 2017.